Company

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product.

The stem cell programmes are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency.  CX601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis.

The company’s commercialised product, ChondroCelect®, for cartilage repair in the knee, was the first approved cell-based product in Europe, and is marketed and distributed by Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI) and Finnish Red Cross Blood Service (FRCBS). TiGenix is based in Leuven, Belgium, and has operations in Madrid , Spain.

Read more...

Products

Pipeline Update

Read more...

Latest News

12 November 2014 - TiGenix completes patient recruitment for the European Phase III trial of Cx601 ahead of schedule (EN - NL - FR)

4 November 2014 - Q3 2014 Business and Financial Update (EN - NL - FR)

17 October 2014 - TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007 (EN - NL)

15 September 2014 - Tigenix to participate or present at key conferences in H2 2014 (EN - NL - FR)

8 September 2014 - European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601 (EN - NL - FR)

Read more...

Events

6-8 October: Stem Cell Meeting on the Mesa, California, USA
Presenter: Eduardo Bravo, Chief Executive Officer
Request meeting

18-22 October: 22nd United European Gastroenterology Week (UEGW), Vienna, Austria
Participant: Mary Carmen Diez, VP Medical Affairs and New Product Commercialisation
Request meeting

3-5 November: BIO-Europe 2014, Frankfurt, Germany
Participant: Claudia Jimenez, Senior Director Business Development
Request meeting

13 November: KBC 3rd Edition Belgian Biotech & Pharma Seminar, New York, USA
Presenter: Eduardo Bravo, Chief Executive Officer

13 November: 2nd Annual EU Advanced Therapies Investor Day, London, UK
Presenter: Claudia D’Augusta, Chief Financial Officer
Request meeting

Read more...